Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .
[Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"].
The LIPID study is a placebo-controlled , double-bind , r and omized trial , performed in 9014 patients with coronary heart disease and total cholesterol levels of 155 to 271 mg/dl . After a mean follow-up of 6.1 years , patients receiving pravastatin ( 40 mg/day ) had significantly ( p < 0.001 ) lower death rate from coronary heart disease ( 24 % ) , lower overall mortality ( 22 % ) and lower incidence of all cardiovascular outcomes ( 20 to 29 % depending on the event ) . Interestingly enough , the reduction in death from coronary heart disease or nonfatal myocardial infa rct ion was observed whatever the initial cholesterol concentration , and already significant if total cholesterol was < 213 mg/dl and LDL cholesterol was < 135 mg/dl . Thus , in secondary prevention , the favourable effect of the statin on the coronary heart disease outcomes is observed even in case of initial cholesterol levels yet considered as " normal "
Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .